A股異動 | 雅本化學(300261.SZ)復牌跌停 未向輝瑞公司供應卡龍酸酐產品
格隆匯2月7日丨雅本化學(300261.SZ)今日復牌跌停,現報21.86元,封單逾47萬手,暫成交4544萬元,最新市值210億元。雅本化學昨日發公吿稱,停牌期間,公司就股票交易異常波動的相關事項進行了核查。公司於2022年1月5日披露的關注函回覆中表述的“卡龍酸酐及其衍生產品從工藝流程上可用於合成輝瑞公司新冠口服藥帕羅維德”,其中卡龍酸酐及其衍生產品指的是化合物,而非特指公司生產的產品,無法確定公司生產的卡龍酸酐及其衍生產品可用於合成輝瑞新冠口服藥。公司與輝瑞公司無任何業務接洽與合作,未與輝瑞公司簽訂合作協議,未向輝瑞公司供應卡龍酸酐產品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.